-
British Medical Journal May 1978A review of the effects of using bromocriptine in Parkinson's disease showed that it rarely helps patients not primarily improved by levodopa. Patients who show late... (Review)
Review
A review of the effects of using bromocriptine in Parkinson's disease showed that it rarely helps patients not primarily improved by levodopa. Patients who show late failure with levadopa and whose response to treatment is declining are helped by combining the two drugs. High cost and severe psychosis are the main disadvantages of bromocriptine, and, although it is not recommended for patients who are doing well on levodopa, it is the best available drug for hospital use in patients who show late failure with levodopa.
Topics: Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced
PubMed: 348261
DOI: 10.1136/bmj.1.6124.1402 -
Heart Failure Reviews Mar 2022Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening form of heart failure (HF). Bromocriptine, a dopamine D2 agonist, has been used as an... (Meta-Analysis)
Meta-Analysis Review
Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening form of heart failure (HF). Bromocriptine, a dopamine D2 agonist, has been used as an adjunctive treatment for PPCM with controversial benefits. A comprehensive literature search was conducted through June 2021. We included studies comparing the outcomes of PPCM with or without bromocriptine use. Pooled risk ratio (RR) with 95% confidence intervals (CI) and I statistics were calculated. Composite major adverse outcomes were defined by a composite of death, need for advanced HF therapies, persistent New York Heart Association (NYHA) functional class III/V, or left ventricular ejection fraction (LVEF) ≤ 35% at 6-month follow-up. LVEF recovery was defined by improvement of LVEF to more than 50%. Eight studies (two randomized-controlled, six observational) involving 593 PPCM patients were included. Bromocriptine use was associated with significantly higher survival (91.6% vs. 83.9%, RR 1.11 p = 0.02). Baseline LVEF was not significantly different between the groups. LVEF at follow-up was significantly higher in the bromocriptine group (53.3% vs. 41.8%, p < 0.001). There was no significant association between bromocriptine use and lower composite major adverse outcomes (13.7% vs. 33.3%, RR 0.60 p = 0.54) or LVEF recovery (46.9% vs. 46.8%, RR 0.94 p = 0.74). In conclusion, the addition of bromocriptine to standard HF treatment in PPCM was associated with significantly higher survival and higher LVEF improvement. No association with lower composite adverse clinical outcomes or LVEF recovery was seen. The findings, although encouraging, warrant larger randomized-controlled studies.
Topics: Bromocriptine; Cardiomyopathies; Female; Heart Failure; Humans; Peripartum Period; Pregnancy; Pregnancy Complications, Cardiovascular; Randomized Controlled Trials as Topic; Stroke Volume; Ventricular Function, Left
PubMed: 34725781
DOI: 10.1007/s10741-021-10185-8 -
The Medical Journal of Australia Nov 1978
Topics: Acromegaly; Bromocriptine; Female; Humans; Parkinson Disease; Pregnancy; Prolactin
PubMed: 739937
DOI: 10.5694/j.1326-5377.1978.tb131650.x -
Pharmacological Reviews Jun 1985Bromocriptine is an ergopeptine derivative and dopamine agonist that predominantly stimulates the striatal D2 non-adenyl cyclase-linked dopamine receptors.... (Review)
Review
Bromocriptine is an ergopeptine derivative and dopamine agonist that predominantly stimulates the striatal D2 non-adenyl cyclase-linked dopamine receptors. Bromocriptine, unlike other dopamine agonists, has mixed "agonist-antagonist" properties at these receptors. The striatal dopamine receptors exist in two different affinity states: a low and a high affinity state. Bromocriptine, unlike other dopamine agonists, does not differentiate between the low and the high affinity state of the D2 receptors, and bromocriptine does not induce a conformational change in these receptors. Bromocriptine, in low doses, is effective in patients with mild to moderate Parkinson's disease, while bromocriptine in higher doses is needed in patients with advanced disease. Both in low doses and in high doses, bromocriptine combined with levodopa is usually more effective than bromocriptine alone. The efficacy of low dose (5-30 mg/day) and high dose (31-100 mg/day) bromocriptine alone and with levodopa was examined in 27 studies encompassing 790 patients. Forty-six % of the studies were done in a double blind manner. In four studies of 79 patients, low dose bromocriptine (16 mg/day) without levodopa resulted in improvement in 58% of the patients. Only 9% of the patients experienced adverse effects. Most of the patients (63%) and mild or moderate Parkinson disease. In seven studies of 143 patients, high dose bromocriptine (56 mg/day) without levodopa resulted in improvement in 62% of patients, but with 27% having adverse effects. Most of these patients (77%) had mild or moderate disease. Diurnal oscillations in performance, the "wearing off" or "on-off" effect, were not seen during treatment with bromocriptine alone. In nine studies of 201 patients, low dose bromocriptine (23 mg/day) and levodopa resulted in improvement in 71% of patients with 26% having adverse effects. Most of these patients (66%) had advanced disease, and many had diurnal oscillations in performance. In seven studies of 367 patients, high dose bromocriptine (48 mg/day) and levodopa resulted in improvement in 58% with 37% having adverse effects. Most of these patients (85%) had advanced disease. The increased effectiveness of bromocriptine in combination with levodopa may be explained as follows. Bromocriptine by itself does not discriminate between the low and the high affinity states of the dopamine receptors.(ABSTRACT TRUNCATED AT 400 WORDS)
Topics: Aged; Animals; Bromocriptine; Drug Administration Schedule; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease; Pergolide; Time Factors
PubMed: 3901046
DOI: No ID Found -
The New England Journal of Medicine Oct 1979
Comparative Study Review
Topics: Acromegaly; Adenoma; Amantadine; Bromocriptine; Female; Galactorrhea; Growth Hormone; Humans; Infertility; Lactation; Levodopa; Male; Parkinson Disease; Pituitary Neoplasms; Pregnancy; Prolactin
PubMed: 384250
DOI: 10.1056/NEJM197910183011606 -
Drugs May 1979Bromocriptine alters the motor behaviour of animals and improves the motor defect of parkinsonism. Changes in movement are accompanied by biochemical changes in the... (Review)
Review
Bromocriptine alters the motor behaviour of animals and improves the motor defect of parkinsonism. Changes in movement are accompanied by biochemical changes in the central nervous system, consistent with the idea that bromocriptine has a dopamine agonist action in the basal ganglia and also in the mesolimbic system and hypothalamus. The overall anti-parkinsonian effect of bromocriptine is similar to that of l-dopa alone or with benserazide (a decarboxylase inhibitor) when optimum doses are used, although individual patients may respond better to 1 drug than to the other.
Topics: Apomorphine; Bromocriptine; Catecholamines; Drug Interactions; Ergolines; Humans; Kinetics; Motor Activity; Movement Disorders; Parkinson Disease; Piribedil; Receptors, Drug; Stereotyped Behavior
PubMed: 37066
DOI: 10.2165/00003495-197917050-00006 -
Diabetes Care Apr 2011
Review
Topics: Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans
PubMed: 21447659
DOI: 10.2337/dc11-0064 -
American Family Physician May 2013
Review
Topics: Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hypoglycemic Agents; Treatment Outcome
PubMed: 23939451
DOI: No ID Found -
American Family Physician Dec 1976
Topics: Acromegaly; Aged; Bromocriptine; Ergolines; Female; Humans; Infertility, Female; Parkinson Disease; Pituitary Neoplasms; Receptors, Dopamine
PubMed: 1036662
DOI: No ID Found -
Lancet (London, England) Oct 1977
Topics: Amenorrhea; Bromocriptine; Female; Humans; Prolactin
PubMed: 71607
DOI: No ID Found